Abstract
Enhanced oral activity is induced in neonatal 6-hydroxydopamine- (6-OHDA-) lesioned rats by systemic administration of the dopamine (DA) D1 receptor agonist SKF 38393 and serotonin (5-HT) 5-HT2A,2C agonistm-chlorophenylpiperazine (m-CPP). The DA D1 receptor antagonist SCH 23390 effectively attenuates the effect of SKF 38393 but notm-CPP. The 5-HT2antagonist mianserin attenuates the effects of bothm-CPP and SKF 38393, suggesting that DA agonist effects are mediated by 5-HT neurochemical systems. To test whether DA and 5-HT agonist effects and interactions might occur within the neostriatum, rats were implanted with permanent injection cannulae, with tips in the ventral striatum. One group of rats was lesioned at 3 days after birth with 6-OHDA HBr (100 µg salt form, in each lateral ventricle; desipramine HCl pretreatment, 20 mg/kg IP, base form, 1 h), while controls received the vehicle in place of 6-OHDA. Cannulae were implanted when rats weighed 200–250 g. During a 1-h observation session SKF 38393 (5 nmol per side) produced 74.3±19.2 oral movements in intact rats and 310.7±97.0 oral movements in 6-OHDA-lesioned rats.m-CPP (10 nmol per side) produced 72.6±15.1 and 274.5±65.0 oral movements in these respective groups. These responses were several-fold greater than the 25.3±7.3 and 41.8±9.5 oral movements in the same groups after saline (0.5 µl per side) (P<0.05). Mianserin (6 nmol per side) alone had no effect on oral activity but attenuated responses to both SKF 38393 andm-CPP in intact and 6-OHDA-lesioned rats. These findings demonstrate that enhanced oral activity responses are produced by intrastriatal SKF 38393 andm-CPP in neonatal 6-OHDA-lesioned rats. Also, when the 5-HT2 receptor antagonist mianserin was administered intrastriatally, induction of oral activity by the DA D1 agonist SKF 38393 was attenuated. These findings indicate that ventral striatum represents at least one brain focus at which DA and 5-HT systems interact to modulate oral activity in rats.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Arnt J (1985) Antistereotypic effects of dopamine D-1 and D-2 antagonists after intrastriatal injection in rats. Pharmacological and regional specificity. Naunyn-Schmiedeberg's Arch Pharmacol 330:97–104
Arnt J, Hyttel J, Perregard J (1987) Dopamine D-1 receptor agonists combined with the selective D-2 agonist, quinpirole, facilitate the expression of oral stereotyped behaviour in rats. Eur J Pharmacol 133:137–145
Arvidsson L-E, Hacksell U, Nilsson JLG, Hjorth S, Carlsson A, Lindberg P, Sanchez D, Wikstrom H (1981) 8-Hydroxy-2-(di-n-propylamino)tetralin, a new centrally acting 5-hydroxytryptamine receptor agonist. J Med Chem 24:921–923
Berger TW, Kaul S, Stricker EM, Zigmond MJ (1985) Hyperinnervation of the striatum by dorsal raphe afferents after dopamine-depleting brain lesions in neonatal rats. Brain Res 366:354–358
Breese GR, Baumeister AA, McCown TJ, Emerick SG, Frye GD, Crotty K, Mueller RA (1984) Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine. J Pharmacol Exp Ther 231:343–354
Breese GR, Baumeister A, Napier TC, Frye GD, Mueller RA (1985a) Evidence that D-1 dopamine receptors contribute to the supersensitive behavioral responses induced byl-dihydroxyphenylalanine in rats treated neonatally with 6-hydroxydopamine. J Pharmacol Exp Ther 235:287–295
Breese GR, Napier TC, Mueller RA (1985b) Dopamine agonist-induced locomotor activity in rats treated with 6-hydroxydopamine at differing ages: functional supersensitivity of D1 dopamine receptors in neonatally-lesioned rats. J Pharmacol Exp Ther 234:447–455
Breese GR, Duncan GE, Napier TC, Bondy SC, Iorio LC, Mueller RA (1986) 6-Hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding. J Pharmacol Exp Ther 240:167–176
Briggs CA, Pollock, NJ, Frail DE, Paxson CL, Rakowski RF, Kang CH, Kebabian JW (1991) Activation of the 5-HT1Creceptor expressed inXenopus oocytes by the benzazepines SCH 23390 and SKF 38393. Br J Pharmacol 104:1038–1044
Bruno JP, Jackson D, Zigmond MJ, Stricker EM (1987) Effects of dopamine-depleting brain lesions in rat pups: role of striatal serotonergic neurons in behavior. Behav Neurosci 101:806–811
Brus R, Kostrzewa RM, Perry KW, Fuller RW (1994) Supersensitization of the oral response to SKF 38393 in neonatal 6-OHDA-lesioned rats is eliminated by neonatal 5,7-dihydroxytryptamine treatment. J Pharmacol Exp Ther 286:231–237
Clow A, Jenner P, Marsden CD (1979) Changes in dopamine-mediated behavior during one year's neuroleptic administration. Eur J Pharmacol 29:365–375
Curzon G, Kennett GA (1990)m-CPP: a tool for studying behavioural responses associated with 5-HT1C receptors. Trends Pharmacol Sci 11:181–182
Delfs JM, Kelley AE (1990) The roleof D1 and D2 dopamine receptors in oral stereotypy induced by dopaminergic stimulation of the ventrolateral striatum. Neuroscience 39:59–67
Descarries L, Soghomonian JJ, Garcia S, Doucet G, Bruno JP (1992) Ultrastructural analysis of the serotonin hyperinnervation in adult rat neostriatum following neonatal dopamine denervation with 6-hydroxydopamine. Brain Res 569:1–13
Dreher JK, Jackson DM (1989) Role of D1 and D2 dopamine receptors in mediating locomotor activity elicited from the nucleus accumbens in rats. Brain Res 487:267–277
Ellison G, See RE (1989) Rats administered chronic neuroleptics develop oral movements which are similar in form to those in humans with tardive dyskinesia. Psychopharmacology 98:564–566
Fletcher GH, Starr MS (1987) Topography of dopamine behaviours mediated by D1 and D2 receptors revealed by intrastriatal injection of SKF 38393, lisuride and apomorphine in rats with a unilateral 6-hydroxydopamine-induced lesion. Neuroscience 20:589–597
Fozard JR (1984) MDL 72222: A potent and highly selective antagonist at neuronal 5-hydroxytryptamine receptors. Naunyn-Schmiedeberg's Arch Pharmacol 326:36–44
Glennon RA (1987) Central serotonin receptors as targets for drug research. J Med Chem 30:1–12
Gong L, Kostrzewa RM (1992) Supersensitized oral response to a serotonin agonist in neonatal 6-OHDA treated rats. Pharmacol Biochem Behav 41:621–623
Gong L, Kostrzewa RM, Fuller RW, Perry KW (1992) Supersensitization of the oral response to SKF 38393 in neonatal 6-OHDA-lesioned rats is mediated through a serotonin system. J Pharmacol Exp Ther 261:1000–1007
Gong L, Kostrzewa RM, Brus R, Fuller RW, Perry KW (1993a) Ontogenetic SKF 38393 treatments sensitize dopamine D1 receptors in neonatal 6-OHDA-lesioned rats. Dev Brain Res 76:59–65
Gong L, Kostrzewa RM, Perry KW, Fuller RW (1993b) Dose-related effects of a neonatal 6-OHDA lesion on SKF 38393- andm-chlorophenylpiperazine-induced oral activity responses of rats. Dev Brain Res 76:233–238
Hamdi A, Kostrzewa, RM (1991) Ontogenic homologous supersensitization of dopamine D1 receptors. Eur J Pharmacol 203:115–120
Hartgraves SL, Randall PK (1986) Dopamine agonist-induced stereotypic grooming and self-mutilation following striatal dopamine depletion. Psychopharmacology 90:358–363
Hoyer D, Engel G, Kalkman HO (1985) Molecular pharmacology of 5-HT1 and 5-HT2 recognition sites in rat and pig brain membranes: radioligand binding studies with [3H]5-HT, [3H]8-OH-DPAT, (−)-[125I]iodocyanopindolol, [3H]mesulergine and [3]Hketanserin. Eur J Pharmacol 118:13–23
Huang NY, Kostrzewa RM (1994) Enhanced oral activity response to A77636 in neonatal 6-hydroxydopamine-lesioned rats. Eur J Pharmacol 253:163–166
Humphrey PPA, Hartig P, Hoyer D (1993) A proposed new nomenclature for 5-HT receptors. Trends Pharmacol Sci 14:233–236
Isaac L, Fowler LJ, Starr BS, Starr MS (1992) Putative neurotoxicity of SKF 38393 and other D1 dopaminergic drugs investigated in rat striatum. J Neurochem 58:1464–1468
Iversen SD, Howells RB, Hughes RP (1980) Behavioral consequences of long-term treatment with neuroleptic drugs. In: Cattabeni F (ed) Adv Biochem Psychopharmacol, vol. 24. Raven Press, New York, pp 305–313
Jicha GA, Salamone JD (1991) Vacuous jaw movements and feeding deficits in rats with ventrolateral striatal dopamine depletion: possible relation to Parkinsonian symptoms. J Neurosci 11:3822–3829
Kelley AE, Lang CG, Gauthier AM (1988) Induction of oral stereotypy following amphetamine microinjection into a discrete subregion of the striatum. Psychopharmacology 95:556–559
Kelley AE, Bakshi VP, Delfs JM, Lang CG (1989) Cholinergic stimulation of the ventrolateral striatum elicits mouth movements in rats: pharmacological and regional specificity. Psychopharmacology 99:542–549
Kelley AE, Delfs JM, Chu B (1990) Neurotoxicity induced by the D1 agonist SKF 38393 following microinjection into rat brain. Brain Res 532:342–346
Koshikawa N, Aoki S, Tomiyama K, Maruyama Y, Kobayashi M (1987) Sulpiride injection into the dorsal striatum increases methamphetamine-induced gnawing in rats. Eur J Pharmacol 133:119–125
Koshikawa N, Aoki S, Hiruta M, Tomiyama K, Kobayashi M, Tsuboi Y, Iwata K, Sumino R, Stephenson JD (1989) Effects of intrastriatal injections of selective dopamine D1 and D2 agonists and antagonists on jaw movements of rats. Eur J Pharmacol 163:227–236
Kostrzewa R (1993) Altered sensitivity of recognition sites for a neurotransmitter in the absence of cdhanges in receptor binding parameters: co-sensitization of an alternate system. In: DasGupta G (ed) Botulinum and tetanus neurotoxins: neurotransmission and biomedical aspects. Plenum Press, New York
Kostrzewa RM (1995) Dopamine receptor supersensitivity. Neurosci Biobehav Rev 19:1–17
Kostrzewa RM, Gong L (1991) Supersensitized D1 receptors mediate enhanced oral activity after neonatal 6-OHDA. Pharmacol Biochem Behav 39:677–682
Kostrzewa RM, Hamdi A (1991) Potentiation of spiperone-induced oral activity in rats after neonatal 6-hydroxydopamine. Pharmacol Biochem Behav 38:215–218
Kostrzewa RM, Brus R, Perry KW, Fuller RW (1993) Age-dependence of a 6-hydroxydopamine lesion on SKF 38393- andm-chlorophenylpiperazine-induced oral activity responses of rats. Dev Brain Res 76:87–93
Kostrzewa RM, Brus R, Kalbfleisch JH, Perry KW, Fuller RW (1994) Proposed animal model of attention deficit hyperactivity disorder. Brain Res Bull 34:161–167
Levin ED, See RE, South D (1989) Effects of dopamine D1 and D2 receptor antagonists on oral activity in rats. Pharmacol Biochem Behav 34:43–48
Leysen JE, Awouters F, Kennis L, Laduron PM, Vandenberk J, Janssen PAJ (1981) Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors. Life Sci 28:1015–1022
Leysen JE, Niemegeers CJE, Van Nueten JM, Laduron PM (1982) [3H]Ketanserin (R 41 468), a selective3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution and functional role. Mol Pharmacol 21:301–314
Luthman J, Bolioli B, Tustsumi T, Verhofstad A, Jonsson G (1987) Sprouting of striatal serotonin nerve terminals following selective lesions of nigro-striatal dopamine neurons in neonatal rat. Brain Res Bull 19:269–274
Middlemiss DN, Fozard JR (1983) 8-Hydroxy-2-(di-n-propylamino)-tetralin discriminates between subtypes of the 5-HT1 recognition sites. Eur J Pharmacol 90:151–153
Milliken GA, Johnson DE (1984) Analysis of messy data. Lifetime Learning Publications, Belmont, Calif.
Molloy AG, Waddington JL (1988) Behavioural responses to the selective D1-dopamine receptor agonist R-SK&F 38393 and the selective D2-agonist RU 24213 in young compared with aged rat. Br J Pharmacol 95:335–342
Murray AM, Waddington JL (1989) The induction of grooming and vacuous chewing by a series of selective D-1 dopamine receptor agonists; two directions of D-1:D-2 interaction. Eur J Pharmacol 160:377–387
Myers RD (1971) Methods in psychobiology. Academic Press, London
Neale RF, Fallon SL, Boyar WC, Wasley JWF, Martin LL, Stone GA, Glaeser BS, Sinton CM, Williams M (1987) Biochemical and pharmacological characterization of CGS 12066B, a selective serotonin-1B agonist. Eur J Pharmacol 136:1–9
Pazos A, Hoyer D, Palacios JM (1984) The binding of serotonergic ligands to the porcine choroid plexus: characterization of a new type of serotonin recognition site. Eur J Pharmacol 106:539–546
Pellegrino LJ, Pellegrino AS, Cushman, AJ (1979) A stereotaxic atlas of the rat brain, 2nd edn. Plenum Press, New York
Pisa M (1988) Motor somatotopy in the striatum of rat: manipulation, biting. Behav Brain Res 27:21–35
Pisa M, Schranz JA (1988) Dissociable motor roles of the rat's striatum conform to a somatotopic model. Behav Neurosci 102:429–440
Rosengarten H, Schweitzer JW, Friedhoff AJ (1983) Induction of oral dyskinesias in naive rats by D1 stimulation. Life Sci 33:2479–2482
Rosengarten H, Schweitzer JW, Egawa J, Friedhoff AJ (1986) Diminished D2 dopamine receptor function and the emergence of repetitive jaw movements. Adv Exp Med Biol 235:159–167
Rupniak NMJ, Jenner P, Marsden CD (1985) Pharmacological characterisation of spontaneous or drug-induced purposeless chewing movements in rats. Psychopharmacology 85:71–79
Rupniak NMJ, Jenner P, Marsden CD (1986) Acute dystonia induced by neuroleptic drugs. Psychopharmacology 88:403–419
Salamone JD, Johnson CJ, McCullough LD, Steinpreis RE (1990) Lateral striatal cholinergic mechanisms involved in oral motor activities in the rat. Psychopharmacology 102:529–534
Scheel-Krüger J, Arnt J (1985) New aspects on the role of dopamine, acetylcholine, and GABA in the development of tardive dyskinesia. In: Casey, Chase, Christensen, Gerlach (eds) Dyskinesia-research and treatment (Psychopharmacology Supplementum 2). Springer, Berlin Heidelberg, pp 46–56
Setler PE, Sarau HM, Zirkle CL, Saunders HL (1978) The central effects of a novel dopamine agonist. Eur J Pharmacol 50:419–423
Smith RD, Cooper BR, Breese GR (1973) Growth and behavioral changes in developing rats treated intracisternally with 6-hydroxydopamine: evidence for involvement of brain dopamine. J Pharmacol Exp Ther 185:609–619
Snyder AM, Zigmond MJ, Lund RD (1986) Sprouting of serotonergic afferents into striatum after dopamine depleting lesions in infant rats: a retrograde transport and immunocytochemical study. J Comp Neurol 245:274–281
Stachowiak MK, Bruno JP, Snyder AM, Stricker EM, Zigmond MJ (1984) Apparent sprouting of striatal serotonergic terminals after dopamine-depleting brain lesions in neonatal rats. Brain Res 291:164–167
Stewart BR, Jenner P, Marsden CD (1989) Induction of purposeless chewing behaviour in rats by 5-HT agonist drugs. Eur J Pharmacol 162:101–107
Towle AC, Criswell HE, Maynard EH, Lauder JM, Joh TH, Mueller RA, Breese GR (1989) Serotonergic innervation of the rat caudate following a neonatal 6-hydroxydopamine lesion: an anatomical, biochemical and pharmacological study. Pharmacol. Biochem Behav 34:367–374
Waddington JL (1990) Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: phenomenology, pathophysiology and putative relationship to tardive dyskinesia. Psychopharmacology 101:431–447
Waddington JL, Gamble ST (1980) Neuroleptic treatment for a substantial proportion of adult life: behavioral sequelae of 9 months haloperidol administration. Eur J Pharmacol 67:363–369
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Plech, A., Brus, R., Kostrzewa, R.M. et al. Enhanced oral activity responses to intrastriatal SKF 38393 andm-CPP are attenuated by intrastriatal mianserin in neonatal 6-OHDA-lesioned rats. Psychopharmacology 119, 466–473 (1995). https://doi.org/10.1007/BF02245863
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02245863